[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sinus-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sinus-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100485962","prospective-study-of-sinonasal-and-skull-base-tumours-management-100485962",false,"NCT05607888","Prospective Study of Sinonasal and Skull-base Tumours Management","Prospective Observational Study of Sinonasal and Skull-base Tumours Management in a Tertiary Referral Otorhinolaryngology Service","Sinonasal_Tu","Inclusion Criteria:\n\n* sinonasal and\u002For skull-base cancer\n* sinonasal disease expanding through the skull-base\n* the patient's written informed consent\n\nExclusion Criteria:\n\n* lateral skull-base disease primarily originating in the temporal bone and without central skull-base involvement","ALL",{"count":19,"type":20},120,"ESTIMATED","5 Years","OBSERVATIONAL","This observational prospective clinical study aims to describe the epidemiology, management and outcome of patients with sinonasal and skull-base pathology (tumours and diseases with malignant clinical characteristics) in a tertiary otorhinolaryngology referral centre. The main questions it aims to answer are:\n\n* what is the caseload of patients with the included pathology in our centre\n* what are the results of management of these cases\n* what are the epidemiological characteristics of included patients\n* what is the quality of life of included patients.",[25,26,27,28,29,30],"Nasal Neoplasm","Nasal Neoplasm Benign","Skull Base Neoplasms","Skull Base Osteomyelitis","Sinonasal Disorder","Sinus Disease","RECRUITING","2026-04-27",{"date":34,"type":35},"2026-04-29","ACTUAL",{"date":37,"type":35},"2022-01-01",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"University Medical Centre Ljubljana","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100551143","phase-2-bupivacaine-and-epinephrine-injection-study-100551143","NCT06456255","Bupivacaine and Epinephrine Injection Study","Bupivacaine With Epinephrine vs Sham Injections During Endoscopic Sinus Surgery: a Double Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 19 years or older\n* Scheduled for primary ESS (including septoplasty)\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* Systemic vasculitis or any bleeding disorders\n* Known or suspected hypersensitivity to bupivacaine or epinephrine\n* Previous sinus surgery\n* Inhaled drug use (i.e., cocaine) in the preceding 6 months\n* Nasal tumors\n* Patients on antiarrhythmics.\n* Patients with history of severe liver illness.\n* Patients identified as high-risk for complications during preoperative assessment with the anesthesiologist (e.g. untreated hypertension, ischemic heart disease, cerebral vascular insufficiency, heart block, peripheral vascular disorder, uncontrolled hyperthyroidism and diabetes)","19 Years",{"count":53,"type":20},80,"INTERVENTIONAL",[56,57],"PHASE2","PHASE3","Endoscopic sinus surgery (ESS) is a common otolaryngologic procedure that aims to remove the partitions that separate the sinus cavities, remove inflamed tissue, and optimize the sinuses for topical medication use. In this procedure, the surgeon will inject a combination of drugs, local anesthetics, and vasoconstrictors, to reduce bleeding and improve visualization. However, previous studies have shown similar results when injected with only saline. In this study, investigators want to determine if the injection of local anesthesic+vasoconstrictor compared to no injection at all makes any difference in improving the surgeon's visualization during an ESS.",[30,60,61],"Anesthesia","Bleeding",[63,64,65],"endoscopic sinus surgery","bupivacaine","epinephrine","2025-05-12",{"date":68,"type":35},"2025-05-15",{"date":70,"type":35},"2024-11-15",{"date":72,"type":20},"2025-07",{"name":74,"class":42},"Amin Javer"]